AÇAhmet Çakır

Ahmet Çakır

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ahmet Çakır has a total of 214 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Assessment of Self-Medication Practices Among Higher-Educated Adults: A Cross-Sectional Survey of Dietary Supplement and OTC Drug Use

    by Nesligül Özdemir-Ayduran, Rümeysa Levent, Ahmet Çakır

    Background and aims: Self-medication, including dietary supplements and over-the-counter drugs, is common worldwide. This study aimed to evaluate self-medication attitudes and behaviours with dietary supplements and OTC drugs among highly educated adults and examine their association with rational drug use awareness.Methods: A cross-sectional survey was conducted between March and May 2025 in a community pharmacy in eastern Türkiye. Adults aged 18–65 with university-level education were recruited via snowball sampling. Data were collected using a structured questionnaire and the validated Adult Rational Drug Use Awareness Scale. Descriptive statistics, non-parametric tests, and chi-square analyses were performed.Results: Data from 300 participants (median age 24 years, 78.3% female) were analysed. Dietary supplements were used by 43.7% of participants, most commonly vitamins, minerals, and probiotics, with doctors (85%) and pharmacists (78.3%) as primary sources of guidance. OTC drugs were used by 39.3%, primarily analgesics and cold/flu medications, with prior experience and convenience cited as the main reasons. Rational drug use awareness scores were significantly higher among non-users of dietary supplements (p = 0.02), whereas no significant difference was observed for OTC use. No significant associations were found between self-medication and demographics.Conclusion: Self-medication with dietary supplements and OTC drugs is prevalent among highly educated adults, with healthcare professionals as primary sources of guidance. Although awareness of rational drug use was high, non-users of dietary supplements had higher scale scores. These findings underscore the need to promote evidence-based self-medication practices and strengthen the advisory role of pharmacists and other healthcare professionals, even among well-educated populations.

  • Open Access

    Association of potentially inappropriate prescribing with drug–drug interactions and medication regimen complexity in geriatric patients: a cross-sectional analytical study

    by Ahmet Çakır, Ahsen Telli̇, Yunus Emre Ayhan, Hasan Memi̇ş, Muhammed Yunus Bektay, Funda Datlı Yakaryılmaz

    Potentially inappropriate prescribing (PIP), potential drug–drug interactions (pDDIs), and elevated medication regimen complexity co-occur frequently

  • Open Access

    Treatment Adherence in Patients with Type 2 Diabetes Mellitus: Associations with Clinical and Metabolic Factors

    by Ahmet Çakır, Hasan Memiş, Ahsen Telli, Esra Tanrıkul, Nesligül Özdemir-Ayduran

    Objective: This study aimed to assess treatment adherence according to antidiabetic treatment regimens and its associations with medication burden and clinical outcomes in patients with type 2 diabetes mellitus (T2DM).Methods: This cross-sectional study was conducted between January and April 2024 in the endocrinology department of a tertiary care hospital. Adult patients diagnosed with T2DM for at least one year were included. Sociodemographic data, comorbidities, diabetes-related complications, treatment and lifestyle characteristics, laboratory parameters (HbA1c and C-peptide), and self-reported adherence were recorded. Treatment adherence was assessed using the validated Turkish version of the Treatment Adherence in Type 2 Diabetes Mellitus (TAT2DM) Scale. The study was approved by the XXX Ethics Committee (approval no: 2023/5237).Results: The study included 198 patients with T2DM. Hypertension was the most common comorbidity, and diabetic peripheral neuropathy was the most frequent complication. The mean TAT2DM score was 85.2 ± 9.2. HbA1c levels were positively correlated with the total number of medications, oral antidiabetic drugs (OADs), and insulin products (p < 0.001), while C-peptide levels were negatively correlated with the number of insulin products (p = 0.010). The total TAT2DM score was negatively associated with the number of insulin products (p = 0.008) and adherence was significantly higher among patients who exercised regularly (p = 0.024). Treatment adherence and HbA1c levels differed significantly across antidiabetic regimens, with higher adherence and HbA1c observed in patients receiving combined insulin and OAD therapy (p

  • Open Access

    Evaluation of albumin utilization, guideline compliance, and cost in intensive care units: a multicenter point prevalence study

    by Ahmet Çakır, Yunus Emre Ayhan, Muhammed Yunus Bektay, Hasan Memiş, Rabia Sarı Küçük, Ayşe Gül Koçoğlu Kınal, Güneş Eskidemir, Eren Güleç, Damla Sosyal, Özge Özmen, et al.

    Intravenous (IV) albumin is widely used in intensive care units (ICUs), yet its use often deviates from evidence-based recommendations, leading to unnecessary costs. This study evaluates the indications for the use of IV albumin in critically ill patients, compliance with the 2024 "Use of Intravenous Albumin" guidelines, and the associated cost burden. A prospective, point prevalence-based observational study was conducted across seven hospitals in Türkiye over one week. Data on IV albumin utilization, guideline compliance, patient demographic and clinical characteristics, and associated costs were collected and analyzed. Statistical analyses included the Kruskal-Wallis test for comparisons of albumin utilization and logistic regression to assess factors influencing its use. Among 385 ICU patients monitored, 56 (14.5%) received IV albumin therapy. The median age was 68 years (Interquartile range-IQR: 54.2-77.7), and 67.9% were male. The most common physician-reported indications for initiating albumin therapy were low serum albumin levels (41.1%), fluid shifts or intravascular volume support (21.4%), and sepsis or septic shock (14.3%). The desired clinical target was achieved in 73.2% of cases; however, guideline compliance was 0%. Albumin use differed significantly across ICU types (p = 0.049), with a median consumption of 667 (IQR: 250-1,083) vials per 1,000 patient-days and an estimated cost of $70,617.86. Logistic regression identified total hospital stay (p = 0.028) and Acute Physiology and Chronic Health Evaluation (APACHE) II score (p = 0.040) as significant predictors, while mechanical ventilation (MV) duration showed borderline significance (p = 0.070). The model's classification accuracy was 78.6%. This study highlights widespread non-compliance with guidelines for IV albumin use in ICUs, resulting in substantial costs. These findings underscore the need to improve compliance with evidence-based guidelines to optimize albumin utilization and reduce economic burden. Future studies should explore the potential impact of targeted interventions, including pharmacist involvement, on improving prescribing practices. Not applicable. Not applicable.

  • Evaluation of Attitudes Regarding the Prevention of Hypertension Development in People with and without a Family History of Hypertension

    by Ahmet Çakır, Hasan Memiş, Sıdıka Yetimoğlu Çakır, Ayşe Yücekaya

    Background and Aim: This study examined the determinants affecting knowledge and attitudes regarding hypertension prevention and assessed the influence of family history on awareness.Methods: A cross-sectional survey was conducted using the validated Turkish Attitudes Scale Towards Prevention of Hypertension (ASPH). Ethical approval was obtained (No: 2025/7447). Data were analysed using SPSS (version 27.0). The normality of distribution was assessed, and non-parametric tests (Mann–Whitney U test and Spearman’s correlation analysis) were applied as appropriate. A p-value of <0.05 was considered statistically significant. Post hoc power analysis indicated a statistical power of 88.8% for group comparisons.Results: A total of 117 adults participated in the “Counsel Your Pharmacist” event on Turkish Pharmacists’ Day. The median [IQR] ASPH score was 103.0 [101.0–115.0]. Among participants with a family history of hypertension, 35 individuals regularly monitored their blood pressure, whereas 43 did not. Mean scores were higher among those who monitored regularly (109.9 ± 9.5) compared to non-monitors (103.6 ± 7.6). A statistically significant association was identified between ASPH scores and physical activity (p < 0.001), smoking (p = 0.015), regular blood pressure monitoring among participants with at least one family member affected by hypertension (p = 0.004), and obesity (p = 0.011). Correlation analysis showed a negative relationship between ASPH scores and weight (p = 0.003), BMI (p = 0.009), and blood pressure, whereas a positive correlation was observed between age and systolic blood pressure (p = 0.022).Conclusion: The findings reveal a limited public understanding of hypertension prevention, underscoring the importance of educational initiatives. Pharmacists serve a vital function in enhancing awareness and encouraging preventive measures against hypertension.

  • FACTORS AFFECTING MEROPENEM TROUGH LEVELS IN CRITICALLY ILL PATIENTS: A THERAPEUTIC DRUG MONITORING STUDY

    by Ahmet Çakır, Hasan Memiş, Zeynep Ülkü Gün, Eren Demirpolat, Deccane Düzenci, Murat Bıçakcıoğlu, Çiğdem Karakükcü

    Objective: This study primarily aimed to determine meropenem the trough level (Cmin) in intensive care unit (ICU), with an exploratory secondary aim of evaluating factors influencing Cmin and clinical cure.Material and Method: This prospective study included adult ICU patients receiving meropenem for ≥48 hours, and Cmin levels were measured using a ready-to-use ELISA kit.Result and Discussion: The study included 38 patients, 26 of whom were male. Mean meropenem Cmin value was found to be 0.40 ± 0.07 mg/l which is statistically different than the target value of 8 mg/l (p < 0.001). We found no statistically significant difference in mean Cmin between the patient groups whose creatinine clearance was smaller than 50 ml/min and not. Erythrocyte and hemoglobin values decreased after meropenem treatment compared to baseline (p < 0.05). C-Reactive Protein (CRP) decreased, and Sequential Organ Failure Assessment (SOFA) values increased after meropenem treatment (p < 0.001). Logistic regression in patients with Systemic Inflammatory Response Syndrome (SIRS) showed that only SOFA reduced the clinical cure rate (OR 0.534, 95% CI 0.311–0.917). In this study, the target 100% fT > MIC < 4×MIC was not achieved with standard or extended meropenem infusion, potentially limiting clinical cure in ICUs with resistant pathogens, highlighting the need for alternative dosing strategies.

  • Open Access

    Determination of insulin therapy perceptions in patients with diabetes mellitus and prediabetes attending the diabetes outpatient clinic

    by Ahmet Cakir, Hasan Memis, Nesligül Ozdemir-Ayduran, Serenay Tarin, Bahri Evren

    Background: Negative perceptions of insulin therapy are common in diabetes mellitus (DM) patients and may delay treatment. Insulin perception has been studied in type 2 diabetics but not type 1 or prediabetics. The aim of this study was to determine the differences in perceptions of insulin use between diabetes types. Methods: This cross-sectional study was conducted at a tertiary care hospital between December 2023 and April 2024. Participants were adult diabetes outpatient clinic patients with T1DM, T2DM, or prediabetes. The validated Insulin Therapy Appraisal Scale (ITAS) quantified patients’ insulin therapy perceptions. Patients who did not use insulin and were in the prediabetes category answered the questions based on their current knowledge about insulin treatment. Higher scores on the positive sub-dimension indicate more favorable perceptions of insulin therapy, whereas higher scores on the negative sub-dimension and total ITAS reflect more negative perceptions. p -value < 0.05 was considered statistically significant. Results: A total of 160 adult patients were included in the study. Patients with T1DM demonstrated significantly higher ITAS positive sub-dimension scores and lower negative sub-dimension and total ITAS scores compared with patients with T2DM and prediabetes ( p < 0.05). No significant differences in ITAS scores were observed between the T2DM and prediabetes groups. Correlation analyses showed that the ITAS positive sub-dimension score was inversely associated with age and C-peptide levels. In contrast, negative sub-dimension and total ITAS scores were positively correlated with age and C-peptide levels but negatively correlated with diabetes duration. Marital status, highest education level, and regular blood glucose monitoring were found to significantly influence insulin perception ( p < 0.05). Female patients exhibited more positive perceptions, whereas insulin users, patients without diabetes-related complications, and those who exercised regularly demonstrated less negative attitudes toward insulin therapy. Conclusion: Patients with T1DM have significantly more positive perceptions of insulin therapy compared with patients with T2DM and prediabetes. Identifying factors influencing insulin-related perceptions may help improve acceptance of insulin therapy and enhance treatment adherence in patients with diabetes. Clinical trial number: N/A.

  • Open Access

    Prospective evaluation of medication-related problems and pharmacist interventions in liver transplant recipients

    by Sena Güzel Karahan, Mefküre Durmuş, Ahmet Çakır, Zeynep Ülkü Gün, Sezai Yılmaz

    Background: Medication-related problems (MRPs) are a common patient safety issue among hospitalized individuals, often associated with reduced quality of life, increased healthcare costs, and higher mortality. Due to the chronic and complex nature of post-transplant care, liver transplant recipients are particularly vulnerable to MRPs. Clinical pharmacists play a critical role in identifying and resolving MRPs, thereby promoting the rational use of medications. The objective of this study was to characterize MRPs among liver transplant recipients and assess the clinical determinants associated with their occurrence. Method: This prospective study was conducted between 5 October 2023 to 31 April 2024 at the Liver Transplantation Institute. A total of 373 hospitalized liver transplant recipients in inpatient wards and intensive care units who were receiving at least one medication were included. Donors and patients not receiving any medication were excluded. The Pharmaceutical Care Network Europe (PCNE) classification system version 9.1 was used to categorize MRPs. Clinical and demographic characteristics of patients with and without MRPs were compared statistically and risk factors were analyzed through logistic regression. Results: Among the 373 patients included in this study, at least one MRP was identified in 311 patients, yielding 620 MRPs in total. A total of 620 interventions were proposed, of which 547 (88.2%) were accepted, while 73 (11.8%) were rejected. The leading causes of MRPs was “dose selection” (C3) was the most common cause (44.2%), followed by “drug selection” (C1) at 26.1%. The presence of at least one comorbidity and acute kidney injury were significant risk factors for the occurrence of MRPs (p < 0.05). Conclusion: To our knowledge, this is the first and most comprehensive study applying the PCNE v.9.1 method to liver transplant recipients hospitalized in both ward and intensive care unit settings. The most prevalent MRPs were related to “treatment effectiveness,” primarily caused by “dose selection” and “drug selection.” Clinical pharmacists and physicians should particularly focus on these aspects when reviewing transplant patients’ medication regimens. The results achieved in this study suggest that clinicians should exercise caution when prescribing new medications to transplant recipients with at least one comorbidity and a history of acute kidney injury.


  • Acyclovir-induced nephrotoxicity and neurotoxicity in a case of viral encephalitis: a case report

    by Bülent Dertli, Sena Güzel Karahan, Kadir Köseoğlu, Ahmet Çakır, Ekrem Salduz

    Viral encephalitis is a hazardous central nervous system disorder requiring immediate antiviral intervention. Acyclovir is the standard treatment for herpes simplex virus (HSV) encephalitis; nevertheless, improper dosing or administration can lead to nephrotoxicity and neurotoxicity. This case describes a 54-year-old male patient admitted for an allergic reaction, who thereafter had incoherent speech, instability and involuntary motions suggestive of HSV encephalitis. Intravenous acyclovir treatment was initiated empirically following cerebrospinal fluid examination. On the third day of therapy, the patient exhibited acute renal impairment, accompanied by hallucinations and significant psychomotor agitation. Following the clinical pharmacist's recommendations, the dosage was adjusted and the infusion period was prolonged to at least 1 hour, predicated on an estimated glomerular filtration rate of 20 mL/min/1,73 m². Subsequent to these surgeries, renal function and neurological status steadily enhanced, enabling a successful resolution of treatment. This example highlights the crucial role of clinical pharmacists in reducing acyclovir-related toxicities via personalised dosage and infusion management.


  • Open Access

    Inappropriate Medication Use in Geriatric Patients: Factors and Management

    by Ahmet Çakır, Hasan Memiş

    In older adults, age-related physiological, anatomical, and metabolic changes, compounded by issues of multimorbidity and polypharmacy, substantially heighten the risk of potentially inappropriate medication (PIM) utilization. PIM, characterized by drug use in which risks surpass benefits, represents a key factor contributing to adverse drug events (ADEs), potential drug-drug interactions (pDDIs), hospitalizations, frailty, and increased healthcare expenditures. PIM arises from multiple factors, including patient-related issues, such as polypharmacy, multimorbidity, cognitive decline, poor adherence, and self-medication; physician-related contributors, such as prescribing cascades, insufficient medication review, and fragmented care; and system-level barriers, such as inadequate medication management programs, limited consultation time, communication gaps, and financial constraints. Among the major consequences of PIM are ADEs, increased risk of falls, higher hospitalization rates, and escalating healthcare expenditures. Several management strategies have been proposed to minimize these risks. Key clinical interventions involve structured medication review and reconciliation, deprescribing, individualized prescribing guided by clinical decision support tools, and measures to enhance adherence. Interventions at the system level, such as comprehensive medication management programs, pharmacist-conducted reviews, collaborative interprofessional approaches, and the incorporation of computerized decision support tools, are vital for promoting safe prescribing. In parallel, patient and caregiver participation, reinforced by education and reporting of adverse events, significantly contributes to the reduction of PIMs. Effectively minimizing PIMs demands a holistic and interdisciplinary framework. Enhancing interprofessional collaboration, supporting patient-centered care initiatives, and examining the long-term outcomes of such strategies are critical for improving pharmacotherapy and healthcare quality in the geriatric population.